Trial description:
A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem
Contact name:
Dr Charles Crawley
Trial start date:
Monday, May 22, 2017
Trial end date:
Friday, December 31, 2021
Trial tumour type:
Haematological
Show on Radiotherapy:
No
